Table 1 The Naranjo scale for adverse drug reaction assessment.
From: Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Question | Yes | No | Don’t know score | |
|---|---|---|---|---|
1. | Are there previous conclusive reports on this reaction? | + 1 | 0 | 0 |
2. | Did the adverse event appear after the suspected drug was administered? | + 2 | − 1 | 0 |
3. | Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was administered? | + 1 | 0 | 0 |
4. | Did the adverse reaction reappear when the drug was readministered? | + 2 | − 1 | 0 |
5. | Are there alternative causes (other than the drug) that could on their own have caused the reaction? | − 1 | + 2 | 0 |
6. | Did the reaction reappear when a placebo was given? | − 1 | + 1 | 0 |
7. | Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? | + 1 | 0 | 0 |
8. | Was the reaction more severe when the dose was increased, or less severe when the dose was decreased? | + 1 | 0 | 0 |
9. | Did the patient have a similar reaction to the same or similar drug in any previous exposure? | + 1 | 0 | 0 |
10. | Was the adverse event confirmed by any objective evidence? | + 1 | 0 | 0 |